"Cohbar press release summarized below. Phase 1b trial comparing CB4211 to placebo demonstrated robust and significant reductions in serum ALT and AST, a significant decrease in glucose levels, and a trend towards lower body weight after four weeks of Rx"

CB4211 - CohBar

Aug 10, 2021